Atazanavir interactions with tenofovir and Viagra included on new US labelling

This article is more than 21 years old. Click here for more recent articles on this topic

The US Food and Drug Administration (FDA) has added new information to the package insert for the latest protease inhibitor (PI) atazanavir (Reyataz), which warns of recently-discovered pharmacokinetic interactions between atazanavir and the non-nucleotide tenofovir (Viread), as well as between atazanavir and PDE5 inhibitors used to treat erectile dysfunction, including sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra).

Tenofovir’s effect on atazanavir

The FDA states:

“Tenofovir decreases the AUC (area under the curve) and Cmin (minimum concentration) of atazanavir.

“When co-administered with tenofovir, it is recommended that atazanavir 300mg is given with ritonavir 100mg and tenofovir 300mg (all as a single daily dose with food). Atazanavir without ritonavir should not be co-administered with tenofovir."

Atazanavir’s effect on tenofovir

Glossary

Food and Drug Administration (FDA)

Regulatory agency that evaluates and approves medicines and medical devices for safety and efficacy in the United States. The FDA regulates over-the-counter and prescription drugs, including generic drugs. The European Medicines Agency performs a similar role in the European Union.

protease inhibitor (PI)

Family of antiretrovirals which target the protease enzyme. Includes amprenavir, indinavir, lopinavir, ritonavir, saquinavir, nelfinavir, and atazanavir.

boosting agent

Booster drugs are used to ‘boost’ the effects of protease inhibitors and some other antiretrovirals. Adding a small dose of a booster drug to an antiretroviral makes the liver break down the primary drug more slowly, which means that it stays in the body for longer times or at higher levels. Without the boosting agent, the prescribed dose of the primary drug would be ineffective.

drug interaction

A risky combination of drugs, when drug A interferes with the functioning of drug B. Blood levels of the drug may be lowered or raised, potentially interfering with effectiveness or making side-effects worse. Also known as a drug-drug interaction.

treatment-experienced

A person who has previously taken treatment for a condition. Treatment-experienced people may have taken several different regimens before and may have a strain of HIV that is resistant to multiple drug classes.

The FDA states:

“Atazanavir increases tenofovir concentrations. The mechanism of this interaction is unknown. Higher tenofovir concentrations could potentiate [make more likely] tenofovir-associated adverse events, including renal [kidney] disorders. Patients receiving atazanavir and tenofovir should be monitored for tenofovir-associated adverse events.

“When co-administered with tenofovir, it is recommended that atazanavir 300mg is given with ritonavir 100mg and tenofovir 300mg (all as a single daily dose with food). Atazanavir without ritonavir should not be co-administered with tenofovir.”

Atazanavir and PDE5 inhibitors

The FDA has added the following to the 'Warnings and Precautions' section:

“Co-administration with atazanavir has not been studied but may result in an increase in PDE5 inhibitor-associated adverse events, including hypotension [low blood pressure], visual changes, and priapism [long-lasting, painful erections].

“Use sildenafil with caution at reduced doses of 25mg every 48 hours with increased monitoring for adverse events. Use tadalafil with caution at reduced doses of 10mg every 72 hours with increased monitoring for adverse events. Use vardenafil with caution at reduced doses of no more than 2.5mg every 72 hours with increased monitoring for adverse events.”

It should be noted that in the US, atazanavir is approved as a single, unboosted PI, taken as two 200mg capsules once daily. This is not the case in the EU and UK: here, two 150mg capsules of atazanavir taken once daily must always be boosted by an additional 100mg dose of ritonavir.

Further information on this website

Atazanavir: positive opinion in EU, but only for treatment-experienced and only when boosted - news story

Warning on atazanavir and tenofovir combination - news story

Atazanavir - overview